An Extended Study of CB7630 (Abiraterone Acetate) in Patients with Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy and Completed Clinical Study COU-AA-003
- Registry ID
- EUCTR2008-002210-22
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE2
- Sponsor
- Janssen Oncology, Inc.
- Start date
- 2008-07-30
- Completion date
- 2012-08-02
- Last update
- 2026-08-16
Conditions
- Hormone refractory prostate cancer
Summary
To provide additional treatment of abiraterone acetate (CB7630) to patients who have completed 12 cycles of abiraterone acetate treatment and continue to receive clinical benefit from such treatment.
Locations
View on source registry